Robotics firms secure funding, advance cardiovascular treatments

San Francisco-based Remedy Robotics secured $62 million in fresh funding to further develop its robotic systems for cardiovascular and endovascular treatments.
The company is developing the N1 system, an AI-enabled robotic platform designed for on-site, remote, or autonomous operation. It uses machine learning to analyze preoperative imaging, simulate cases, and provide real-time image registration for endovascular procedures.
Remedy aims to expand access to specialized neurovascular, coronary, and peripheral vascular care. The funding will support a key trial in partnership with the University of California, with the goal of obtaining FDA approval for neurovascular intervention.
The Series B funding round was led by DCVC, with new investors including UC Investments, Skip Capital, and Hostplus.
In a separate development, Capstan Medical announced the first U.S. transcatheter mitral valve replacement using its investigational robot. The procedure, performed at The Christ Hospital in Cincinnati, was part of an FDA-authorized early feasibility study.
Capstan’s robotic system aims to simplify complex mitral valve procedures
Capstan’s Compass robotic system combines a flexible multi-axis catheter, robotic navigation, and a novel valve implant. It provides catheter stability and control for precise positioning of the mitral valve implant.
The technology has the potential to benefit patients who cannot undergo conventional heart surgery, according to Dr. Santiago Garcia, who led the procedure. This milestone follows Capstan’s first-in-human robot-assisted mitral valve replacement procedures in Chile.
While transcatheter aortic valve replacement is a well-established procedure, transcatheter mitral valve replacement (TMVR) has been slower to develop due to the mitral valve’s complex anatomy. Capstan’s system aims to address this challenge by providing enhanced precision and control during the procedure.
With Remedy working with over 100 hospitals worldwide and Capstan securing $110 million in funding in 2024, both companies are well-positioned to drive innovation in their respective fields. The successful completion of remote neurointerventional procedures with Remedy’s N1 system and Capstan’s first U.S. TMVR case mark significant milestones in the development of robotic-assisted cardiovascular interventions.
Remedy’s N1 System Advances with Remote Procedures
Remedy Robotics’ N1 system has been used to perform remote neurointerventional procedures, with a successful case completed in October 2025. This milestone builds on the company’s global reach, now partnering with over 100 hospitals worldwide.
